Covidien said Monday that its Tri-Staple technology platform has achieved more than $1 billion in sales.
Launched in mid-2010, the technology enables surgeons to use staplers in a broader range of tissue thicknesses than before, the company said in a press release. The Covidien product line that incorporates this technology is employed in a wide range of laparoscopic surgical procedures.
“Reaching this milestone in less than three years from launch is a significant accomplishment,” Bryan Hanson, group president of Covidien’s surgical solutions unit, said in a statement. “We intend to continue investing in and expanding the Tri-Staple technology portfolio.”
Covidien, a global provider of health care products, is incorporated in Dublin but has its headquarters in Mansfield. It had 2012 revenue of $11.9 billion and employs 43,000 worldwide.